Missouri – The Food and Drug Administration (FDA) is allowing clinical trials of remdesivir to help COVID-19 patients. It is uncertain if these vaccines will help with COVID-19 or not.
The FDA’s emergency authorization of remdesivir is administered intravenously in critical patients by health care providers. Remdesivir will be given to adults and children hospitalized with severe COVID-19.
Kansas University Professor Anthony Fehr has been working on coronaviruses for over a decade. Fehr sheds some light on remdesivir that is under clinical trial.
The Missouri Highway Patrol this past week was helping distribute remdesivir across Missouri.
United States Secretary of Health and Human Services Alex Azar said FDA’s emergency authorization of remdesivir has showed promising results and could be a big step in battling COVID-19.
“National Institute of Health, FDA, and scientists across America and around the world have worked tirelessly with patients to get us this new potential treatment for COVID-19,” said Azar. “The seamless cooperation between government and private industry to get the clinical trials for COVID-19 out is moving in record time.”